COMMUNIQUÉS West-GlobeNewswire

Mentions légales

* Temps de fermeture de l’ulcère avec HydroTac® : moins de 15 semaines alors que les données de la littérature montrent que 40-60% des ulcères nécessitent 20 à 24 semaines pour cicatriser. (1) Mikosiński, J. et al. Clinical assessment of a foam dressing containing growth factor-enhancing hydrated polyurethanes. J Wound Care.2018;27(9):608-18. HydroTac® : DM de classe IIb – Fabricant : PAUL HARTMANN AG – Organisme notifié : CE 0123. Lire attentivement les instructions figurant dans la notice (et/ou sur l’étiquetage). Remboursé par les organismes d’assurance maladie : consultez les modalités sur le site www.ameli.fr. Réf : 14122018. Date de création : Décembre 2018

Oncology Venture has established bridge loan facility
22/03/2019 - 08:51
Press release Hørsholm, Denmark and Cambridge, MA, US, March 22, 2019 – Oncology Venture A/S announced today that its share has received observation status by Nasdaq Stockholm AB, following the publication of its Annual [...]
Herantis Pharma Plc: Change in the number of shares and voting rights
22/03/2019 - 09:00
Herantis Pharma Plc: Change in the number of shares and voting rights Herantis Pharma Plc Company release 22 March 2019 at 10:00 am Herantis Pharma Plc (''Herantis'' or the ''Company'') announced a directed share issue [...]
Crown Bioscience présentera les dernières avancées en matière de plateformes précliniques et translationnelles à au congrès annuel de l'AACR 2019
22/03/2019 - 10:23
15 affiches présenteront les données des nouveaux modèles d'évaluation des nouveaux traitements du cancer SAN DIEGO, 22 mars 2019 (GLOBE NEWSWIRE) -- Crown Bioscience, une société mondiale de services de recherche et de [...]
Exactus Applauds CVS’s Decision to Sell CBD Products
22/03/2019 - 11:30
Exactus Inc. Anticipates Many More National Drugstores to Follow Suit DELRAY BEACH, Fla., March 22, 2019 (GLOBE NEWSWIRE) -- Exactus Inc. (OTCQB:EXDI / OTCQB:EXDID) , a healthcare company pursuing opportunities in Hemp [...]
UCB SA : Convocation à l'assemblée générale des actionnaires qui se tiendra à Bluepoint Brussels
22/03/2019 - 07:00
UCB - société anonyme Allée de la Recherche 60, 1070 Bruxelles n° d’entreprise 0403.053.608 (RPM Bruxelles) (« UCB SA » ou la « Société ») CONVOCATION À L’ASSEMBLÉE GÉNÉRALE DES ACTIONNAIRES QUI SE TIENDRA À BLUEPOINT [...]
UCB SA/NV: Convening Notice to attend the general meeting of shareholders to be held at Bluepoint Brussels
22/03/2019 - 07:00
*** Unofficial English translation – For convenience purposes only *** UCB SA/NV - Public Limited Liability Company Allée de la Recherche 60, 1070 Brussels Enterprise nr. 0403.053.608 (RLE Brussels) (" UCB SA/NV " or [...]
Novartis plans for Alcon spin-off on April 9, 2019
22/03/2019 - 07:01
Alcon obtained approval for listing on SIX Swiss Exchange and New York Stock Exchange Alcon will seek effectiveness of Form 20-F registration statement from the US Securities and Exchange Commission Alcon will enter key [...]
Financial Statement Bulletin
22/03/2019 - 08:00
BBS-Bioactive Bone Substitutes Plc Company Announcement March 22, 2019 at 9:00 am BBS-Bioactive Bone Substitutes Plc (BBS) Interim Report 1.1.-30.6.2018 (unaudited) January-June shortly (comparison season 1-6/2017) The [...]
RAMSAY GENERALE DE SANTE : lancement d'une augmentation de capital
22/03/2019 - 08:20
COMMUNIQUE DE PRESSE Ramsay Générale de Santé annonce le lancement d'une augmentation de capital avec maintien du droit préférentiel de souscription de 625 millions d'euros environ dans le cadre du refinancement de l' [...]
Gritstone Oncology Announces First Patient Dosed in a Clinical Study Evaluating its Personalized Immunotherapy, GRANITE-001
21/03/2019 - 21:00
EMERYVILLE, Calif., March 21, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer [...]
TearLab Corporation Reports Fourth Quarter and Full Year 2018 Financial Results
21/03/2019 - 21:01
ESCONDIDO, Calif., March 21, 2019 (GLOBE NEWSWIRE) -- TearLab Corporation (OTCQB:TEAR) (“TearLab” or the “Company”) today reported its consolidated financial results for the fourth quarter and twelve months ended [...]
Oxford Immunotec Announces Chief Financial Officer Transition
21/03/2019 - 21:01
OXFORD, United Kingdom and MARLBOROUGH, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that Richard [...]
Forty Seven Inc. to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, March 28, 2019
21/03/2019 - 21:01
MENLO PARK, Calif., March 21, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today [...]
Opiant Pharmaceuticals, Inc. Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update
21/03/2019 - 21:05
Addiction and Drug Overdose Pipeline Supported by Strong Cash Position; Expected to be in Range of $17M-$20M at End of 2019 SANTA MONICA, Calif., March 21, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant [...]
Conatus Announces Top-line Results from ENCORE-NF Phase 2b Clinical Trial in NASH Fibrosis
21/03/2019 - 21:05
Shortfall on Primary Endpoint Shifts Focus for Emricasan to Ongoing NASH Cirrhosis Trials SAN DIEGO, March 21, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced top-line results from [...]
Sienna Biopharmaceuticals Promotes Alexander Azoy to Chief Financial Officer and Appoints Sean Andrews to Leadership Team as Vice President, Investor Relations
21/03/2019 - 21:05
-- John W. Smither Departing for Personal Reasons WESTLAKE VILLAGE, Calif., March 21, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced [...]
Sol-Gel Technologies Reports Full Year 2018 Financial Results and Provides Corporate Update
21/03/2019 - 21:05
Company met all milestones in 2018 and this year expects to report Phase III top-line results for Epsolay ® and TWIN, potentially best-in-class papulopustular rosacea and acne vulgaris topical medications Recent [...]
Altimmune to Announce Year End 2018 Financial Results on April 2
21/03/2019 - 21:15
GAITHERSBURG, Md., March 21, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the year ended December 31, [...]
Translate Bio Announces Fourth Quarter and Full Year 2018 Financial Results and Reviews Recent Highlights
21/03/2019 - 21:29
LEXINGTON, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat [...]

COMMUNIQUÉS West-GlobeNewswire

Pages